Delhi's All India Institute of Medical Sciences (AIIMS) is set to begin the clinical trials of the indigenous Bharat Biotech's COVID-19 vaccine "Covaxin" on children from Monday. Until now, AIIMS Patna has started the Paediatric clinical trial of Covaxin. On May 11, the Drug Controller General of India (DCGI) gave nod to Bharat Biotech to conduct clinical trials on children on May 11.
Meanwhile, 18 children will include in the first phase of the trial. The target has been set to complete this entire test in eight weeks. In this, the effect of the vaccine on children and the body's immunity will be studied. Let us tell you that the clinical trial of this vaccine in AIIMS Patna has started on June 3 on children aged 12 to 18 years.
Earlier, Member (Health) of Niti Aayog VK Paul had said, "Covaxin approved by the Drugs Controller General of India (DCGI), for Phase II/III clinical trials in the age group of 2 to 18 years." Significantly, experts are constantly predicting that the third wave of coronavirus will have an impact on children.
Recently, Paul also said that Ahmedabad-based Zydus Cadila is also conducting trials of its Covid-19 vaccine on children in the age group of 12-18 years. However, the company is yet to apply for licensure in the next 10-14 days. Meanwhile, the Zydus vaccine, ZyCov-D developed with support from the Centre's National Biopharma Mission. As part of the Biotechnology Industry Research Assistance Council, department of biotechnology.
Also Read:
